Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators

Drug Discovery Today

Volumn 12, Issue 19-20, 2007, Pages 860-869

  Kremoser, Claus ^a   Albers, Michael ^a   Burris, Thomas P ^b   Deuschle, Ulrich ^a   Koegl, Manfred ^c  

^a PHENEX PHARMACEUTICALS AG   (Germany)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; PEPTIDE; RALOXIFENE; RECEPTOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE NUCLEAR RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

CELL ASSAY; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; DNA FINGERPRINTING; DRUG ACTIVATION; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; RECEPTOR BINDING; REVIEW;

ANIMALS; BINDING SITES; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPRECIPITATION; LIGANDS; PEPTIDES; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 35148833056     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.07.025     Document Type: Review

References (72)

1. Mangelsdorf D.J., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
2. Gronemeyer H., et al. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3 (2004) 950-964
3. Aranda A., and Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81 (2001) 1269-1304
4. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
5. Black L.J., et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69
6. Clemett D., and Spencer C.M. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60 (2000) 379-411
7. Baumann H., et al. Refined solution structure of the glucocorticoid receptor DNA-binding domain. Biochemistry 32 (1993) 13463-13471
8. Schwabe J.W., et al. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75 (1993) 567-578
9. Bourguet W., et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375 (1995) 377-382
10. Bledsoe R.K., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 (2002) 93-105
11. Nolte R.T., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
12. Brzozowski A.M., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
13. Benoit G., et al. Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell. Biol. 14 (2004) 369-376
14. Perissi V., and Rosenfeld M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol. 6 (2005) 542-554
15. Lonard D.M., and O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125 (2006) 411-414
16. Metivier R., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
17. Shang Y., et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
18. Metivier R., et al. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 7 (2006) 161-167
19. Xu H.E., et al. Structural basis for antagonist-mediated recruitment of nuclear corepressors by PPARalpha. Nature 415 (2002) 813-817
20. Shiau A.K., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
21. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
22. Smith C.L., et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11 (1997) 657-666
23. Szapary D., et al. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol. Endocrinol. 13 (1999) 2108-2121
24. Wang Q., et al. Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors. Mol. Endocrinol. 18 (2004) 1376-1395
25. Dotzlaw H., et al. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol. Cell Endocrinol. 213 (2003) 79-85
26. Jackson T.A., et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11 (1997) 693-705
27. Schulz M., et al. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J. Biol. Chem. 277 (2002) 26238-26243
28. Benko S., et al. Molecular determinants of the balance between corepressor and co-activator recruitment to the retinoic acid receptor. J. Biol. Chem. 278 (2003) 43797-43806
29. Ruse Jr. M.D., et al. Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4alpha1: modulation by the F domain. Mol. Cell Biol. 22 (2002) 1626-1638
30. Albers M., et al. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 281 (2006) 4920-4930
31. Zechel C. Synthetic retinoids dissociate coactivator binding from corepressor release. J. Recept. Signal Transduct. Res. 22 (2002) 31-61
32. Germain P., et al. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415 (2002) 187-192
33. Bramlett K.S., and Burris T.P. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 86 (2003) 27-34
34. Coghlan M.J., et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 17 (2003) 860-869
35. Burgermeister E., et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20 (2006) 809-830
36. Jaber B.M., et al. The pure estrogen receptor antagonist ICI 182,780 promotes a novel interaction of estrogen receptor-alpha with the 3′,5′-cyclic adenosine monophosphate response element-binding protein-binding protein/p300 coactivators. Mol. Endocrinol. 20 (2006) 2695-2710
37. Rocchi S., et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 (2001) 737-747
38. Fujimura T., et al. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. Biol. Pharm. Bull. 29 (2006) 423-429
39. Kodera Y., et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 275 (2000) 33201-33204
40. Issa L.L., et al. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J. Bone Miner. Res. 17 (2002) 879-890
41. Takeyama K., et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell Biol. 19 (1999) 1049-1055
42. Eelen G., et al. Altered Vitamin D receptor-coactivator interactions reflect superagonism of Vitamin D analogs. J. Steroid Biochem. Mol. Biol. 97 (2005) 65-68
43. Bramlett K.S., et al. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol. Endocrinol. 15 (2001) 909-922
44. Inaba Y., et al. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators. Mol. Pharmacol. 71 (2007) 1298-1311
45. Heery D.M., et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997) 733-736
46. Torchia J., et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387 (1997) 677-684
47. Hu X., and Lazar M.A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 (1999) 93-96
48. Perissi V., et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13 (1999) 3198-3208
49. Nagy L., et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13 (1999) 3209-3216
50. Savkur R.S., and Burris T.P. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 63 (2004) 207-212
51. Folkertsma S., et al. The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor alpha ligand-binding domain. Mol. Endocrinol. 21 (2007) 30-48
52. Ozers M.S., et al. Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization. Mol. Endocrinol. 19 (2005) 25-34
53. Iannone M.A., et al. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 18 (2004) 1064-1081
54. Iannone M.A., et al. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 44 (2001) 326-337
55. Paige L.A., et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3999-4004
56. Fields S., and Song O. A novel genetic system to detect protein-protein interactions. Nature 340 (1989) 245-246
57. Albers M., et al. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol. Cell. Proteomics 4 (2005) 205-213
58. Kazmin D., et al. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol. Endocrinol. 20 (2006) 1201-1217
59. Kim S.H., et al. A proteomic microarray approach for exploring ligand-initiated nuclear hormone receptor pharmacology, receptor selectivity, and heterodimer functionality. Mol. Cell. Proteomics 4 (2005) 267-277
60. Zajchowski D.A., et al. Identification of selective estrogen receptor modulators by their gene expression fingerprints. J. Biol. Chem. 275 (2000) 15885-15894
61. Frasor J., et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64 (2004) 1522-1533
62. Kwon Y.S., et al. Sensitive ChIP-DSL technology reveals an extensive estrogen receptor alpha-binding program on human gene promoters. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4852-4857
63. Carroll J.S., et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38 (2006) 1289-1297
64. Guan H.P., et al. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 19 (2005) 453-461
65. Hoekstra W.J., et al. Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling. J. Med. Chem. 48 (2005) 2243-2247
66. Rosenfeld M.G., et al. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
67. Onate S.A., et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273 (1998) 12101-12108
68. Ma H., et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell Biol. 19 (1999) 6164-6173
69. Oesterreich S., et al. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol. Endocrinol. 14 (2000) 369-381
70. Berry M., et al. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9 (1990) 2811-2818
71. Tzukerman M.T., et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8 (1994) 21-30
72. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19 (2005) 833-842